WuXi PharmaTech Kicks off this Year’s Science Seminar Series by Welcoming Dr. Edward J.J. Grabowski

2007-02-05 12:55 1165

SHANGHAI, China, Feb. 5 /Xinhua-PRNewswire/ -- WuXi PharmaTech, China's leading provider of pharmaceutical R&D outsourcing services started its 2007 Science Seminar Series off on a big step by welcoming Dr. Edward J.J Grabowski. Dr. Grabowski, retired VP of Chemistry (Process Research) at the Merck Research Laboratories, a division of Merck & Company (NYSE: MRK), delighted eager young scientists with his expertise and experience in Process Research and Development.

(Logo: )

The WuXi PharmaTech Science Seminar Series is a monthly program that invites top minds in the pharmaceutical industry to share their wealth of experience and years of expertise with the next generation of scientists. As well, WuXi PharmaTech’s scientific staff gains a new perspective on the industry.

Dr. Grabowski, a 39-year veteran of Merck, held engaging lectures on Process Research and Development full of anecdotes and insightful personal experiences from his many years with Merck Research Laboratories.

Dr. Grabowski recently retired as VP of chemistry (Process Research) at the Merck Research Laboratories. During his almost four decades in the industry, Dr. Grabowski co-authored approximately 100 research papers, and was a co-inventor on over 50 U.S. patents. As well, he has been a guest lecturer to over 150 symposia and held courses in Process Research at prestigious universities such as the Massachusetts Institute of Technology, and the University of Wisconsin.

“To be the best, we must learn from the best”, commented Dr. Ge Li, Chairman and CEO of the company. “We are honored to welcome Dr. Edward Grabowski to share his experiences and knowledge of Process Research Chemistry with our scientists. As a growing company, we value the wisdom of an industry leader. Our scientists are fortunate to learn from such a visionary chemist,” continued Dr. Li.

About WuXi PharmaTech Co., Ltd.

Founded in 2001, Shanghai-based WuXi PharmaTech is China's leading drug R&D service company. As a research-driven and customer-focused company, WuXi PharmaTech offers global pharmaceutical and biopharmaceutical companies a diverse, value-added, and fully integrated portfolio of outsourcing services ranging from discovery chemistry, and process chemistry to service biology, bioanalytical chemistry, and large scale GMP manufacturing. WuXi PharmaTech assists its global partners in shorting the cycle and lowering the cost of drug discovery and development by providing cost-effective and efficient outsourcing solutions that save our clients both time and money. Currently, our client list consists of 19 of the top 20 pharmaceutical, and 8 of the top 10 biopharmaceutical companies. For more information, please visit: .

Source: WuXi PharmaTech Co., Ltd.
Related Stocks: